Stanford University and Telomolecular Corp. Sign Global Licensing Agreement

Share Article

Stanford University and Telomolecular Corp. agree to the global licensing of Synthetic DNA Nanocircles in the treatment of human aging and disease.

Synthetic DNA Nanocircles for Elongation of Telomere Repeats.

Telomolecular Corp., a biomedical nanotechnology company that focuses on the repair of chromosomal telomeres, and Stanford University, Palo Alto, CA, through Stanford’s Office of Technology Licensing, agree to an exclusive in vivo licensing agreement on the use of Stanford’s “Synthetic DNA Nanocircles for Elongation of Telomere Repeats.” The terms of the agreement permit Telomolecular to develop and commercialize nanocircles in the treatment of organismal aging and disease.

Synthetic DNA Nanocircles are a biomedical nanotechnology invented by Dr. Eric Kool and colleagues of Stanford University. These nanometer-sized circular DNAs have been shown to elongate chromosomal telomeres in vitro. They consist of DNA bases arranged in a sequence that templates the lengthening of telomeres by repeated addition of new TTAGGG sequences. Nanocircles have shown promise in telomere elongation in human tissues. By combining nanocircles with new proprietary gene therapy and delivery technologies, Telomolecular believes that nanocircles might work efficiently in living animals. Successful commercial products based on this technique might lead to effective therapies for many crippling degenerative diseases such as macular degeneration, atherosclerosis, and dyskeratosis congenita, and may additionally prove useful in addressing generalized aging-related problems of long-lived organisms like humans.

There have been promising advances in demonstrating the use of fully synthetic biomedical platforms. While Telomolecular intends to stay committed to delivering natural proteins known to elongate telomeres, in the long-term, once synthesis and manufacturing capabilities have been mastered, there are reasons to believe that Synthetic DNA Nanocircles might become a therapeutically superior and more cost efficient way of elongating telomeres in vivo.

According to Matthew A. Sarad, Chief Executive Officer of Telomolecular “We are excited to work with Stanford University on this project. By establishing programs for the delivery of both natural and synthetic telomere elongation agents in vivo, Telomolecular is further establishing its position as a leader in an emerging field. Particularly we've placed attention on the "cost effectiveness and simplicity" of certain emerging biomedical nanotechnologies.”

About Stanford Office of Technology Licensing

Stanford University’s Office of Technology Licensing (OTL) is a service-oriented interface between the Stanford University of Stanford and University inventors and private enterprises. OTL mission is to promote the transfer of Stanford technology for society’s use and benefit while generating unrestricted income to support research and education.

About Telomolecular

Telomolecular develops nanotechnologies capable of delivering large-molecule proteins across human cell membranes. The corporation's primary focus is on the transport of therapeutic agents that lengthen and repair chromosomal telomeres in living animals. Successful therapies based on this tactic may offset, and potentially reverse, many devastating age-related diseases and perhaps address many symptoms and signs associated with human aging.

Contacts - Telomolecular Investor Relations

Matthew A. Sarad

(916) 410-8681

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Matthew Sarad
Visit website